In this review, the major physiological and metabolic actions of PACAP and VIP through their specific receptors are summarized, and the most recent advances in understanding the role of PACAP and VIP in the pathogenesis of metabolic diseases and obesity disorders are described. Here, ADCYAP1 is linked to obesity disorder.